top of page


graphic 2.png

Halucenex is a life sciences development company with a focus on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. Halucenex operates a 6000 sqft medical facility in Windsor, Nova Scotia with 6 treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.


  • cGMP Grade Psychedelic Compounds

  • Psychedelic-assisted psychotherapy treatment facility

  • Clinical trial infrastructure

  • Modern laboratory equipment

  • Genetics testing facilities

  • Finished product testing

  • Cultivation facilities

  • Extraction lab

  • HPLC Lab


Market Focus - Veterans and Emergency Responders


Halucenex is focused on researching psilocybin, psilocybin-derivatives and other psychedelic medicine for the purposes of treating clients suffering from PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:


  • researching how unique compounds present in specific mushroom strains work together to facilitate treatment;

  • performing clinical trials on psilocybin-assisted psychotherapy and microdosing on mental health; and

  •  compiling and analyzing patient experience/feedback


William (Bill) Fleming (President & CEO and Veteran)


David James PhD Chemistry (Quality Assurance)

Lisa Batten PhD (Clinical Director)


Niall J. Buckley (Clinical Lead Physician)


Brenda Perks (Psychedelic Assisted Psychotherapist RN.BN.NP.CLNC.)

Don Hunter (Senior Vice President Business Development and Strategic Partnerships)

bottom of page